Entity

Time filter

Source Type

Portland, OR, United States

Lord M.S.,University of New South Wales | Cheng B.,University of New South Wales | McCarthy S.J.,HemCon Inc | Jung M.,University of New South Wales | Whitelock J.M.,University of New South Wales
Biomaterials | Year: 2011

Chitosan has been shown to promote initial wound closure events to prevent blood loss. Platelet adhesion and activation are crucial early events in these processes after traumatic bleeding leading to thrombus formation. Platelet adhesion to chitosan was found to be enhanced in the presence of adsorbed plasma and extracellular matrix proteins and was found to be primarily mediated by α IIbβ 3 integrins, while α 2β 1 integrins were found to be involved in platelet adhesion to collagen and perlecan. Platelets were found to be activated by chitosan, as shown by an increase in the expression of α IIbβ 3 integrins and P-selectin, while the extent of activation was modulated by the presence of proteins including perlecan and fibrinogen. Collagen-coated chitosan was found to activate platelets to the same extent as either chitosan or collagen alone. These data support the role of plasma and extracellular matrix proteins in promoting chitosan mediated platelet adhesion and activation supporting the hypothesis that chitosan promotes wound healing via these interactions. © 2011 Elsevier Ltd. Source


Grant
Agency: Department of Defense | Branch: Navy | Program: SBIR | Phase: Phase I | Award Amount: 70.00K | Year: 2010

We will develop a novel hemostatic, antimicrobial, resorbable, nanofiber dressing utilizing proven hemorrhage control technology in combination with novel advanced technologies. The nanofiber dressing will be prepared using scaleable Nanospider™ electrospinning technology. Nanofiber Based Dressing Constructs (NBDCs) can be prepared to have physical and chemical attributes that closely resemble natural biologic matrix forms such as the body’s extracellular matrix. Because of these characteristics, NBDCs are readily conformable with complex injuries and provide for rapid delivery of hemostatic and antimicrobial functionality. We will investigate the use of a new absorbable, hemostatic, electrospinnable chitosan derivative. The chitosan derivative resorbs rapidly and meets ISO 10993 requirements for a resorbable implantable material. HemCon has performed allergenic human trials using the original base chitosan and has demonstrated absence of shrimp or other allergic responses in hypersensitive individuals. Chitosan surface area, in conjunction with shear promotes platelet activation of clotting. The very high specific surface area of chitosan in the NBDC provides significant advantages in controlling hemorrhage and addressing contamination. HemCon will partner with Haemostatix Ltd to further enhance hemostatic activity by the conjugation of a fibrinogen binding peptide (GPRP) to the NBDC. Initial studies demonstrate that peptide surface coating will control hemorrhage within one minute.


The inventive device and methods described herein address the introduction of a safe and effective freeze-dried biological product, and particularly a plasma product, to a subject in need thereof. The present invention relates to a multifunctional, staged closure device, which also is described as a lyophilization container for plasma (LCP). The device and methods described herein address how to reproducibly achieve a low moisture and substantially oxygen-free atmosphere within a finally hermetically sealed biocompatible low aspect plastic vessel within a standard shelf-stoppering freeze dryer. The present inventive device and methods provide a freeze-dried plasma product that is fully traceable, preserves the constituent plasma activity, is readily prepared in a sterile fashion, is stable, ensures ease of storage and permits rapid reconstitution and delivery to a patient.


Improved hemostatic agents take the form of granules or particles that can be used to stanch, seal, or stabilize a site of hemorrhage, including a noncompressible hemorrhage.


Improved hemostatic agents take the form of granules or particles that can be used to stanch, seal, or stabilize a site of hemorrhage, including a noncompressible hemorrhage.

Discover hidden collaborations